Kết quả tìm kiếm - Keikawus Arastéh

  • Đang hiển thị 1 - 17 kết quả của 17
Tinh chỉnh kết quả
  1. 1
    POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients

    POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients Bằng Anton Pozniak, Keikawus Arastéh, Jean‐Michel Molina, Beatriz Grinsztejn, Sandra De Meyer, Tom Van de Casteele, Sabrina Spinosa‐Guzman

    Được phát hành 2008
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    The late‐presenting <scp>HIV</scp>‐infected patient 30 years after the introduction of <scp>HIV</scp> testing: spectrum of opportunistic diseases and missed opportunities for early diagnosis

    The late‐presenting <scp>HIV</scp>‐infected patient 30 years after the introduction of <scp>HIV</scp> testing: spectrum of opportunistic diseases and missed opportunities for early... Bằng Daniela Tominski, Juri Katchanov, Dominik Driesch, MB Daley, Anna Liedtke, A.L.C. Schneider, Hortense Slevogt, Keikawus Arastéh, Hartmut Stocker

    Được phát hành 2016
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

    Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomi... Bằng David A. Cooper, Damien V. Cordery, Roberto Zajdenverg, Kiat Ruxrungtham, Keikawus Arastéh, Frank Bergmann, José L. de Andrade Neto, Joseph Schérer, Ricardo L. Chaves, Patrick Robinson

    Được phát hành 2016
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

    An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance Bằng Brian Gazzard, Anton Pozniak, Willy Rosenbaum, Guy-Patrick Yeni, Schlomo Staszewski, Keikawus Arastéh, Karin de Dier, Monika Peeters, Brian Woodfall, Justin Stebbing, Gerben A.E. van 't Klooster

    Được phát hành 2003
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients

    Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients Bằng Josep M. Gatell, Javier O Morales‐Ramirez, Debbie Hagins, Melanie Thompson, Keikawus Arastéh, Christian Hoffmann, Sorin Rugină, Olayemi Osiyemi, Simona Escoriu, Robin Dretler, Charlotte Harvey, Xia Xu, Hedy Teppler

    Được phát hành 2014
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

    Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials Bằng François Raffi, Anita Rachlis, Cynthia Brinson, Keikawus Arastéh, Miguel Górgolas, Clare Brennan, Keith A. Pappa, Steve Almond, Catherine Granier, W. Garrett Nichols, Robert L. Cuffe, Joseph J. Eron, Sharon Walmsley

    Được phát hành 2014
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

    Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients Bằng Gatell, Josep M, Morales-Ramirez, Javier O, Hagins, Debbie P, Thompson, Melanie, Keikawus, Arasteh, Hoffmann, Christian, Rugina, Sorin, Osiyemi, Olayemi, Escoriu, Simona, Dretler, Robin, Harvey, Charlotte, Xu, Xia, Teppler, Hedy

    Được phát hành 2014
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease

    Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease Bằng Christian Hoffmann, Holger Schmid, Markus Müller, Christian Teutsch, Jan van Lunzen, Stefan Eßer, Timo Wolf, Christoph Wyen, Michael Sabranski, Heinz‐August Horst, Stefan Reuter, Martin Vogel, Hans Jäger, Johannes R. Bogner, Keikawus Arastéh

    Được phát hành 2011
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

    Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results Bằng Joel E. Gallant, Ellen Koenig, Jaime Andrade‐Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Graeme Moyle, Giuliano Rizzardini, Jan Fehr, Yapei Liu, Lijie Zhong, Christian Callebaut, Javier Szwarcberg, Martin S. Rhee, Andrew Cheng

    Được phát hành 2013
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

    Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia Bằng Adriano Lazzarin, Bonaventura Clotet, David A. Cooper, Jacques Reynes, Keikawus Arastéh, Mark Nelson, Christine Katlama, Hans-Jürgen Stellbrink, Jean-François Delfraissy, Joep M. A. Lange, Les Huson, Ralph DeMasi, Cynthia Wat, John Delehanty, Claude Drobnes, Miklos Salgo

    Được phát hành 2003
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study

    Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study Bằng Marcus Hentrich, Marcel Berger, Christoph Wyen, Jan Siehl, Jürgen K. Rockstroh, Markus Müller, Gerd Fätkenheuer, Elisabeth Seidel, Maike Nickelsen, Timo Wolf, Ansgar Rieke, Dirk Schürmann, Ralf Schmidmaier, M. Planker, Jürgen Alt, Franz Mosthaf, Andreas Engert, Keikawus Arastéh, Christian Hoffmann

    Được phát hành 2012
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

    Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection Bằng Stefan Zeuzem, Tarik Asselah, Peter Angus, Jean‐Pierre Zarski, Dominique Larrey, Beat Müllhaupt, Ed Gane, Marcus Schuchmann, Ansgar W. Lohse, Stanislas Pol, Jean‐Pierre Bronowicki, Stuart K. Roberts, Keikawus Arastéh, Fabien Zoulim, Markus H. Heim, Jerry O. Stern, George Kukolj, Gerhard Nehmiz, Carla Haefner, Wulf O. Boecher

    Được phát hành 2011
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

    Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study Bằng Graham Smith, W. Keith Henry, Daniel Podzamczer, Marı́a del Mar Masiá, Christopher Bettacchi, Keikawus Arastéh, Hans Jaeger, Marie-Aude Khuong-Josses, María Luisa Montes-Ramírez, Hans‐Jürgen Stellbrink, Yazdan Yazdanpanah, Gary Richmond, Kenneth Sutton, Feifan Zhang, Cynthia McCoig, M H St Clair, Kati Vandermeulen, Rodica Van Solingen‐Ristea, Kimberly Y. Smith, David A. Margolis, William Spreen

    Được phát hành 2021
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

    Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection Bằng Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora, Vadim Pokrovsky, Edgar T. Overton, Pierre‐Marie Girard, Shinichi Oka, Sharon Walmsley, Chris Bettacchi, Cynthia Brinson, Patrick Philibert, Johan Lombaard, Marty St. Clair, Herta Crauwels, Susan L. Ford, Parul Patel, Vasiliki Chounta, Ronald D’Amico, Simon Vanveggel, David Dorey, Amy Cutrell, Sandy Griffith, David A. Margolis, Peter Williams, Wim Parys, Kimberly Y. Smith, William Spreen

    Được phát hành 2020
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

    Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial Bằng Richard B. Pollard, Jürgen K. Rockstroh, Giuseppe Pantaleo, David M. Asmuth, Barry Peters, Adriano Lazzarin, Felipe García, Kim Ellefsen, Daniel Podzamczer, Jan van Lunzen, Keikawus Arastéh, Dirk Schürmann, Bonaventura Clotet, William D. Hardy, Ronald T. Mitsuyasu, Graeme Moyle, Andreas Plettenberg, Martin Fisher, Gerd Fätkenheuer, Margaret A. Fischl, Babafemi Taiwo, Ingebjørg Baksaas, Darren Jolliffe, Stefan Persson, Øyvind Jelmert, Arnt-Ove Hovden, Maja A. Sommerfelt, Vidar Wendel‐Hansen, Birger Sørensen

    Được phát hành 2014
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

    Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials Bằng Mark Nelson, Keikawus Arastéh, Bonaventura Clotet, David A. Cooper, Keith Henry, Christine Katlama, Jacob Lalezari, Adriano Lazzarin, Julio Montaner, Mary O’Hearn, Peter J. Piliero, Jacques Reynes, Benoît Trottier, Sharon Walmsley, Calvin Cohen, Joseph J. Eron, Daniel R. Kuritzkes, Joep M. A. Lange, Hans-Jürgen Stellbrink, Jean-François Delfraissy, Neil Buss, Lucille Donatacci, Cynthia Wat, Lynn Smiley, T. M. Wilkinson, Adeline Valentine, Denise Guimaraes, Ralph DeMasi, Jain Chung, Miklos Salgo

    Được phát hành 2005
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

    Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials Bằng Giuliano Rizzardini, Edgar T. Overton, Chloe Orkin, Susan Swindells, Keikawus Arastéh, Miguel Górgolas Hernández-Mora, Vadim Pokrovsky, Pierre-Marie Girard, Shinichi Oka, Jaime Andrade‐Villanueva, Gary Richmond, Axel Baumgarten, Mar Masiá, Gulam Latiff, Sandy Griffith, Conn Harrington, Krischan J Hudson, Marty St. Clair, Christine L. Talarico, Parul Patel, Amy Cutrell, Veerle Van Eygen, Ronald D’Amico, Joseph Mrus, Sterling Wu, Susan L. Ford, K.-C. Chow, Jeremy Roberts, Angela Wills, Nicola Walters, Simon Vanveggel, Rodica Van Solingen‐Ristea, Herta Crauwels, Kimberly Y. Smith, William Spreen, David A. Margolis

    Được phát hành 2020
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: